Description

Sinflorix Vaccines

Ingredients

• Each 0.5 ml dose contains pneumococcal polysaccharides from 13 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F, and 23F).

Dosage

• The recommended dosage is a single 0.5 ml injection administered subcutaneously.

Indications

• Sinflorix Vaccines are indicated for active immunization against invasive pneumococcal disease caused by the serotypes included in the vaccine.

Contraindications

• Do not administer Sinflorix Vaccines to individuals with a known hypersensitivity to any component of the vaccine.

Directions

• The vaccine should be administered by healthcare professionals according to standard vaccination practices.

Scientific Evidence

• Sinflorix Vaccines have demonstrated efficacy in preventing invasive pneumococcal disease in clinical trials. The vaccine’s formulation, containing a combination of pneumococcal polysaccharides, has shown to induce a robust immune response against the targeted serotypes.
• Furthermore, studies have indicated that Sinflorix Vaccines provide long-lasting protection against pneumococcal infections, reducing the incidence of severe disease and associated complications.

Additional Information

• It is essential to adhere to the recommended vaccination schedule to ensure optimal protection against pneumococcal disease.
• Patients should be informed about the benefits of Sinflorix Vaccines in preventing potentially life-threatening pneumococcal infections and the importance of vaccination in maintaining public health.